Washington, D.C. 20549


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Deniger Drew

(Last) (First) (Middle)
8030 EL RIO ST.


(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Alaunos Therapeutics, Inc. [ TCRT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
VP, Research and Development
3. Date of Earliest Transaction (Month/Day/Year)
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $2.11 09/15/2022 A 305,000 (1) 09/14/2032 Common Stock 305,000 $0.00 305,000 D
Explanation of Responses:
1. The options will vest in a series of sixteen equal quarterly installments measured from September 15, 2022, with the first vesting occurring on December 15, 2022, subject to the Reporting Person's continuous service through each such date.
Exhibit List - Exhibit 24 - Power of Attorney
/s/ Melinda Lackey, Attorney-in-Fact 09/19/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                               Power of Attorney

     Know all by these presents, that the undersigned hereby makes, constitutes
and appoints each of Melinda Lackey and Michael Wong, or either of them acting
singly, and with full power of substitution and re- substitution, the
undersigned's true and lawful attorney-in-fact (each of such persons and their
substitutes being referred to herein as the "Attorney-in-Fact"), with full power
to act for the undersigned and in the undersigned's name, place and stead, in
any and all capacities, to:

     1.   Prepare, execute, and submit to the Securities and Exchange Commission
          ("SEC") a Form ID, including amendments thereto, and any other
          documents necessary or appropriate to obtain codes and passwords
          enabling the undersigned to make electronic filings with the SEC of
          reports required or considered by the Attorney-in-Fact to be advisable
          under Section 13 or Section 16 of the Securities Exchange Act of 1934
          (the "Exchange Act") or any rule or regulation of the SEC;

     2.   Prepare, execute and submit to the SEC, Alaunos Therapeutics, Inc.
          (including any successor or assign, the "Company"), and/or any
          national securities exchange on which the Company's securities are
          listed any and all reports (including any amendments thereto) the
          undersigned is required to file with the SEC, or which the
          Attorney-in-Fact considers it advisable to file with the SEC, under
          Section 13 or Section 16 of the Exchange Act or any rule or regulation
          thereunder, or under Rule 144 under the Securities Act of 1933
          ("Rule 144"), with respect to the any security of the Company,
          including Forms 3, 4 and 5, Schedules 13D and 13G, and Forms 144; and

     3.   Obtain, as the undersigned's representative and on the undersigned's
          behalf, information regarding transactions in the Company's equity
          securities from any third party, including the Company and any
          brokers, dealers, employee benefit plan administrators and trustees,
          and the undersigned hereby authorizes any such third party to release
          any such information to the Attorney-in-Fact.

     The undersigned acknowledges that:

          a)   This Power of Attorney authorizes, but does not require,
               the Attorney-in-Fact to act in his or her discretion on
               information provided to such Attorney-in-Fact without independent
               verification of such information;

          b)   Any documents prepared or executed by the Attorney-in-Fact on
               behalf of the undersigned pursuant to this Power of Attorney will
               be in such form and will contain such information as the
               Attorney-in-Fact, in his or her discretion, deems necessary or

          c)   Neither the Company nor the Attorney-in-Fact assumes any
               liability for the undersigned's responsibility to comply with the
               requirements of Section 13 or Section 16 of the Exchange Act or
               Rule 144, any liability of the undersigned for any failure to
               comply with such requirements, or any liability of the
               undersigned for disgorgement of profits under Section 16(b) of
               the Exchange Act; and

          d)   This Power of Attorney does not relieve the undersigned from
               responsibility for compliance with the undersigned's obligations
               under Section 13 or Section 16 of the Exchange Act, including,
               without limitation, the reporting requirements under Section 13
               or Section 16 of the Exchange Act.

     The undersigned hereby grants to the Attorney-in-Fact full power and
authority to do and perform each and every act and thing requisite, necessary or
advisable to be done in connection with the foregoing, as fully, to all intents
and purposes, as the undersigned might or could do in person, hereby ratifying
and confirming all that the Attorney-in-Fact, or his or her substitute or
substitutes, shall lawfully do or cause to be done by authority of this Power of

     This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 4 or 5 or Schedules 13D or 13G
or Forms 144 with respect to the undersigned's holdings of and transactions in
securities of the Company, unless earlier revoked by the undersigned in a signed
writing delivered to the Attorney-in-Fact. This Power of Attorney revokes all
previous powers of attorney with respect to the subject matter of this Power of

     The signature may be delivered via facsimile, electronic mail (including
any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform
Electronic Transactions Act, the Electronic Signatures and Records Act or other
applicable law, e.g., or other transmission method and any
signature so delivered shall be deemed to have been duly and validly delivered
and be valid and effective for all purposes.

     IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as
of September 19, 2022.

                                        Drew Caldwell Deniger

                                        /s/ Drew Deniger